Purpose - Methods - The IFCT 1703-R2D2 trial is a multicenter, nonrandomized phase II study. Patients with -mutated, advanced NSCLC who progressed after ≥ 1 platinum-based treatment were enrolled. Patients received pertuzumab at a loading dose of 840 mg and 420 mg thereafter; trastuzumab at an 8 mg/kg loading dose and 6 mg/kg thereafter; and...
-
March 1, 2022 (v1)Journal articleUploaded on: February 22, 2023
-
2014 (v1)Journal article
Background: The IFCT-GFPC 0502 phase III study reported prolongation of progression-free survival with gemcitabine or erlotinib maintenance vs. observation after cisplatin–gemcitabine induction chemotherapy for advanced non-small-cell lung cancer (NSCLC). This analysis was undertaken to assess the incremental cost-effectiveness ratio (ICER) of...
Uploaded on: March 26, 2023 -
March 2022 (v1)Journal article
Background Three to 9% of low-grade pre-invasive bronchial lesions progress to cancer. This study assessed the usefulness of an intensive bronchoscopy surveillance strategy in patients with bronchial lesions up to moderate squamous dysplasia. Methods SELEPREBB ( NCT00213603 ) was a randomized study conducted in 17 French centers. After baseline...
Uploaded on: December 3, 2022